GlassScriptPhysician profile
Robert Joseph Collins
NPI 1225477425
$10,534.41
in general payments reported to CMS, 2019-2025
70 companies · $2,513 in 2025
The $2,513 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $581 · 2021: $58.65 · 2022: $1,887 · 2023: $2,276 · 2024: $2,520 · 2025: $2,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,308.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,035.12 | 2019-2025 | |
| Janssen Biotech, INC. | $583.41 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Celgene Corporation | $522.39 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $518.46 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $517.71 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $452.24 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $394.30 | 2019-2025 | Alunbrig, Ninlaro, Exkivity |
| Lilly USA, LLC | $362.18 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Abbvie INC. | $305.89 | 2019-2025 | Venclexta |
| Astellas Pharma US INC | $301.70 | 2019-2025 | Xtandi, Xospata, Padcev |
| Incyte Corporation | $280.71 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $266.36 | 2019-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $254.35 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Heron Therapeutics, INC. | $253.63 | 2022 | |
| Gilead Sciences, INC. | $231.28 | 2019-2025 | Trodelvy |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $227.35 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Emd Serono, INC. | $209.33 | 2022-2025 | Bavencio, Tepmetko |
| Seagen INC. | $208.21 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Amgen INC. | $205.42 | 2019-2023 | Kyprolis |
| Eagle Pharmaceuticals, INC. | $187.24 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $181.12 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.82 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $154.22 | 2022-2024 | Qinlock |
| Octapharma USA, INC. | $151.98 | 2022 | |
| Array Biopharma INC | $141.69 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Genzyme Corporation | $140.16 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.97 | 2022-2025 | Libtayo |
| Novocure INC. | $123.90 | 2020 | |
| Exelixis INC. | $121.35 | 2022-2025 | Cabometyx |
| Puma Biotechnology, INC. | $120.65 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $118.73 | 2022 | |
| Foundation Medicine, INC. | $114.67 | 2020 | |
| Rigel Pharmaceuticals, INC. | $99.90 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Ipsen Biopharmaceuticals, INC | $85.71 | 2023-2024 | Somatuline Depot, Onivyde |
| Eisai INC. | $80.40 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $79.83 | 2023-2025 | Orgovyx |
| Glaxosmithkline, LLC. | $77.33 | 2023-2025 | Ojjaara, Blenrep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.01 | 2019-2025 | Gilotrif |
| Kyowa Kirin, INC. | $68.29 | 2020-2024 | Poteligeo |
| Janssen Pharmaceuticals, INC | $67.11 | 2022-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $65.87 | 2022-2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $64.50 | 2023-2025 | Xpovio |
| Adc Therapeutics America, INC. | $57.83 | 2023-2025 | |
| Mirati Therapeutics, INC. | $56.45 | 2023-2024 | Krazati |
| Pharmaessentia USA Corporation | $52.52 | 2024 | Besremi |
| Aveo Pharmaceuticals, INC. | $51.17 | 2022-2023 | Fotivda |
| Servier Pharmaceuticals LLC | $48.14 | 2023-2025 | |
| Sobi, INC | $45.07 | 2023-2024 | |
| Beigene USA, INC. | $35.47 | 2023-2024 | Brukinsa |
| Blueprint Medicines Corporation | $34.56 | 2022-2025 | Ayvakit |
| Beone Medicines USA, INC. | $32.71 | 2025 | Brukinsa, Tevimbra |
| Morphosys, US INC. | $29.40 | 2022-2023 | Monjuvi |
| Acrotech Biopharma INC. | $28.87 | 2025 | Beleodaq |
| Secura Bio, INC. | $27.30 | 2020 | |
| Immunocore Limited | $26.46 | 2025 | Kimmtrak |
| Pharmacyclics LLC, An Abbvie Company | $26.06 | 2019-2022 | |
| Tersera Therapeutics LLC | $24.14 | 2025 | Zoladex |
| Taiho Oncology, INC. | $20.63 | 2024 | |
| Cti Biopharma Corp. | $19.98 | 2023 | Vonjo |
| Genmab U.S., INC. | $18.70 | 2024 | Epkinly |
| Macrogenics, INC. | $18.68 | 2022 | |
| Spectrum Pharmaceuticals INC. | $17.57 | 2024 | Rolvedon |
| Epizyme, INC. | $17.28 | 2022 | |
| G1 Therapeutics, INC. | $17.12 | 2023 | Cosela |
| Dentsply Sirona INC | $16.07 | 2020 | |
| Coherus Oncology, INC. | $14.32 | 2025 | Loqtorzi |
| Dova Pharmaceuticals | $12.82 | 2020 | |
| Agios Pharmaceuticals, INC. | $11.73 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $11.17 | 2019 | |
| Advanced Accelerator Applications | $10.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.